Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

Related NPSP
3 Niche ETFs Breaking Out
Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on NPS Pharmaceuticals (NASDAQ: NPSP), and raised its price target from $13.00 to $15.00.

Jefferies noted, “As expected, FDA's AdComm panel voted for recommending approval of Gattex unanimously. Panel also voted favorably on NPSP's proposed REMS (10-1), supporting likely timely approval (PDUFA date, 12/30/12). With potential approval of a 2nd product Natpara in ~mid-2014, we see significant upside in NPSP shares from current levels. Reiterate Buy.”

NPS Pharmaceuticals closed on Tuesday at $10.19.

Latest Ratings for NPSP

Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (NPSP)

View Comments and Join the Discussion!

Partner Center